This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Mar 9;381(9869):783-5.

doi: 10.1016/S0140-6736(12)61954-0.

Everolimus for renal angiomyolipoma in tuberous sclerosis

Prasanna Sooriakumaran¹, Christopher J Anderson

Affiliations

PMID: 23312828
DOI: 10.1016/S0140-6736(12)61954-0

Comment

Everolimus for renal angiomyolipoma in tuberous sclerosis

Prasanna Sooriakumaran et al. Lancet. 2013.

. 2013 Mar 9;381(9869):783-5.

doi: 10.1016/S0140-6736(12)61954-0.

Authors

Prasanna Sooriakumaran¹, Christopher J Anderson

Affiliation

¹ Department of Urology, St George’s NHS Trust, London SW17 0QT, UK. sooriakumaran@gmail.com

PMID: 23312828
DOI: 10.1016/S0140-6736(12)61954-0

No abstract available

PubMed Disclaimer

Comment on

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Bissler JJ, et al. Lancet. 2013 Mar 9;381(9869):817-24. doi: 10.1016/S0140-6736(12)61767-X. Lancet. 2013. PMID: 23312829 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations